Included in the formulation
АТХ:D.10.A.X.03 Azelanic acid
Pharmacodynamics:Has a bacteriostatic effect on Propionibacterium acnes and Staphylococcus epidermidis.
The anti-acne action is due to inhibition of the synthesis of cellular proteins of aerobic and anaerobic microorganisms (violates glycolysis). Growth inhibition Propionibacterium acnes, Staphylococcus epidermidis. Reducing the formation of microcosmodes, normalization (inhibition) of the process of keratinization of the epidermis, a decrease in the thickness of the stratum corneum, the number and width of the distribution of filagrin (keratogialin component) in the epidermis. Oppresses the hyperactivity of melanocytes, inactivates free radicals, due to which the hypopigmental effect of the drug is manifested.
Pharmacokinetics:The drug penetrates the epidermis and dermis, absorption from the surface of the epidermis into the blood plasma - up to 4%, excreted by the kidneys mainly in an unchanged form.
Indications:Seborrheic dermatitis, Acne vulgaris, pathological hyperpigmentation such as melasma (for example, chloasma), rosacea.
XII.L20-L30.L21 Seborrheic dermatitis
XII.L60-L75.L70.0 Acne vulgaris [acne vulgaris]
XII.L60-L75.L71 Rosacea
XII.L80-L99.L81 Other disorders of pigmentation
XII.L80-L99.L81.1 Chloasma
Contraindications:Hypersensitivity, children under 12 years.
Carefully:Breastfeeding, pregnancy.
Pregnancy and lactation:Category FDA - B. The drug penetrates through the placental barrier, penetrates into breast milk. During pregnancy and during lactation, the drug should be used only if the intended benefit to the mother exceeds the possible risk to the fetus and the baby. It is necessary to avoid applying cream on the area of the mammary glands before feeding.
Dosing and Administration:Dosage regimen is individual, apply topically. On average, the drug is applied to the previously cleaned skin surface 2 times a day, the treatment course can be up to 3 months.
Side effects:From the skin and subcutaneous fat: seborrhea, acne, depigmentation of the skin, cheilitis.
General disorders at the site of administration: itching, burning, erythema at the application site, peeling, pain, dryness, irritation at the application site, paresthesia, dermatitis, edema at the application site.
Immune system disorders: drug hypersensitivity, worsening of the course of bronchial asthma.
Overdose:Not described, treatment is symptomatic.
Interaction:Not described.
Special instructions:Avoid contact with mucous membranes.
Impact on the ability to drive vehicles and manage mechanisms
The drug does not affect the management of vehicles and occupations of other potentially hazardous activities requiring increased concentration of attention and high speed of psychomotor reactions.